

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

INSIDE INFORMATION
ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE
H SHARE FULL CIRCULATION BY THE COMPANY

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 29 August 2025 (the “**Announcement**”) in relation to the proposed implementation of conversion of certain Domestic Shares into H Shares. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company has submitted an application to the CSRC on behalf of 29 shareholders of the Company (the “**Shareholders**”) in respect of the conversion of an aggregate of 208,390,308 Domestic Shares held by such 29 Shareholders into the H Shares (the “**H Share Full Circulation**”). The Board is pleased to announce that on 29 April 2026, the Company received the “Notification of filing on the ‘Full Circulation’ of Domestic Unlisted Shares of Sunshine Lake Pharma Co., Ltd.” (the “**Filing Notice**”) dated 27 April 2026 and issued by the CSRC regarding the H Share Full Circulation. Accordingly, the Company has completed the filing with the CSRC in respect of the H Share Full Circulation. Pursuant to the Filing Notice, if the Company fails to complete the Conversion and Listing of the H Share Full Circulation within 12 months from the date of issuance of the Filing Notice, the Company shall update the filing materials if it intends to proceed with it.

Details of the participating Shareholders in relation to the H Share Full Circulation are set out as follows:

Name of participating Shareholders	Number of Domestic Shares to be converted into H Shares	Approximate percentage of the total issued shares of the Company (including treasury shares) upon completion of the Conversion and Listing (%)
1. Shenzhen HEC Industrial Development Co., Ltd.* (深圳市東陽光實業發展有限公司)	29,745,526	5.16
2. Guangdong HEC Technology Holding Co., Ltd.* (廣東東陽光科技控股股份有限公司)	50,989,649	8.84
3. Yidu Junjiafang Equity Investment Limited (L.P.)* (宜都俊佳芳股權投資合夥企業(有限合夥))	7,651,813	1.33
4. Yidu Shuaixinwei Equity Investment Limited (L.P.)* (宜都帥新偉股權投資合夥企業(有限合夥))	30,607,250	5.31
5. Yidu Yingwenfang Equity Investment Limited (L.P.)* (宜都英文芳股權投資合夥企業(有限合夥))	11,477,892	1.99
6. Yidu Fangwenwen Equity Investment Limited (L.P.)* (宜都芳文文股權投資合夥企業(有限合夥))	11,477,892	1.99
7. Pingxiang Junyuan Tongchuang Enterprise Management Center (L.P.)* (萍鄉市君源同創企業管理中心(有限合夥))	439,986	0.08
8. Gongqingcheng Jianyi Investment Partnership (L.P.)* (共青城漸益投資合夥企業(有限合夥))	5,719,816	0.99
9. Shenzhen Dicheng Investment Center (L.P.)* (深圳市帝成投資中心(有限合夥))	2,111,933	0.37
10. Shenzhen Wenzheng Changxing Venture Capital Enterprise (L.P.)* (深圳市穩正長興創業投資企業(有限合夥))	1,185,761	0.21
11. Jiaxing Aomin Equity Investment Partnership (L.P.)* (嘉興傲旻股權投資合夥企業(有限合夥))	819,693	0.14
12. Ningbo Daxie Hansheng Enterprise Management Co., Ltd.* (寧波大榭漢勝企業管理有限公司)	2,199,929	0.38
13. Zhuhai Kangyang Management Consulting Partnership (L.P.)* (珠海康陽管理諮詢合夥企業(有限合夥))	6,599,787	1.14
14. Zhuhai Kangpu Equity Investment Partnership (L.P.)* (珠海康普股權投資合夥企業(有限合夥))	4,201,864	0.73

Name of participating Shareholders	Number of Domestic Shares to be converted into H Shares	Approximate percentage of the total issued shares of the Company (including treasury shares) upon completion of the Conversion and Listing (%)
15. Wenzhou Zhenrui Equity Investment Partnership (L.P.)* (溫州臻瑞股權投資合夥企業(有限合夥))	1,851,241	0.32
16. Zhuhai Hengqin Cuiheng New Era Industrial Investment Fund (L.P.)* (珠海橫琴翠亨新時代產業投資基金(有限合夥))	1,209,961	0.21
17. Wuhan Mige Investment Management Partnership (L.P.)* (武漢米格投資管理合夥企業(有限合夥))	1,957,938	0.34
18. Jiaxing Jiayu Equity Investment Partnership (L.P.)* (嘉興嘉鈺股權投資合夥企業(有限合夥))	8,799,718	1.53
19. Ruyuan Yao Autonomous County Yinyuan Electric Power Group Co., Ltd.* (乳源瑤族自治縣銀源電力集團有限公司)	1,099,965	0.19
20. Guiyang SME Development Fund (L.P.)* (貴陽中小企業發展基金(有限合夥))	1,099,965	0.19
21. Hunan Xingxiang Jiacheng Private Equity Investment Fund Partnership (L.P.)* (湖南興湘佳誠私募股權投資基金合夥企業(有限合夥))	549,982	0.10
22. Shenzhen Qinzhi Kanghong Venture Capital Partnership (L.P.)* (深圳勤智康宏創業投資合夥企業(有限合夥))	2,089,934	0.36
23. Guangdong Shunyin Industry Finance Investment Co., Ltd.* (廣東順銀產融投資有限公司)	1,539,951	0.27
24. Yidu Guotong Investment Development Co., Ltd.* (宜都市國通投資開發有限責任公司)	2,199,929	0.38
25. Huzhou Rongrui Equity Investment Partnership (L.P.)* (湖州融睿股權投資合夥企業(有限合夥))	4,993,839	0.87
26. Shenzhen Xinshi Xinxing Industry M&A Equity Investment Fund Partnership (L.P.)* (深圳信石信興產業併購股權投資基金合夥企業(有限合夥))	3,255,896	0.56

Name of participating Shareholders	Number of Domestic Shares to be converted into H Shares	Approximate percentage of the total issued shares of the Company (including treasury shares) upon completion of the Conversion and Listing (%)
27. Guangzhou Yuanshi No. 1 Venture Capital Partnership (L.P.)* (廣州源石壹號創業投資合夥企業(有限合夥))	1,513,551	0.26
28. Jiaxing Xingsheng Dongyan Investment Partnership (L.P.)* (嘉興興晟東研投資合夥企業(有限合夥))	9,679,689	1.68
29. Jiaxing Xingsheng Guangchuang Investment Partnership (L.P.)* (嘉興興晟廣創投資合夥企業(有限合夥))	1,319,958	0.23
Total	<u>208,390,308</u>	<u>36.14</u>

The shareholding structure of the Company (taking into account of the treasury shares) before and upon the completion of the Conversion and Listing is set out as follows:

Type of shares	Before the completion of the Conversion and Listing		Upon the completion of the Conversion and Listing	
	Number of shares	Approximate percentage of total issued shares of the Company (%)	Number of Shares	Approximate percentage of total issued shares of the Company (%)
Domestic Shares	463,943,215	80.45	255,552,907	44.32
H Shares	<u>112,712,832</u>	<u>19.55</u>	<u>321,103,140</u>	<u>55.68</u>
Total	<u>576,656,047</u>	<u>100.00</u>	<u>576,656,047</u>	<u>100.00</u>

As of the date of this announcement, the details of the implementation plan of the H Share Full Circulation and the Conversion and Listing have not been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in compliance with the Listing Rules as and when appropriate.

The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
29 April 2026

As at the date of this announcement, the executive directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.

* *For identification purposes only*